Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Other financing activities (2018 - 2020)

Standard Biotools (LAB) reported Other financing activities of $18000.0 for Q2 2020, up 20.0% year-over-year from $15000.0 in Q3 2019, and down 94.96% on a QoQ basis from $357000.0 in Q1 2020.

Standard Biotools (LAB) has 3 years of Other financing activities data on file, last reported at $18000.0 in Q2 2020.

  • Quarterly Other financing activities rose 20.0% year-over-year to $18000.0 in Q2 2020, while the trailing twelve-month figure through Jun 2021 was $375000.0 (down 25.45% YoY) and the FY2022 annual result came in at $12.5 million, changed N/A from the prior year.
  • Other financing activities declined to $18000.0 in Q2 2020 per LAB's latest filing, from $357000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $2.6 million in Q2 2018 and bottomed at $15000.0 in Q2 2019.
  • The 3-year median for Other financing activities is $98000.0 (2018), against an average of $420625.0.
  • The widest annual swing landed in 2019, when Other financing activities tumbled 99.41%; it then increased 20.0% in 2020.
  • Tracing LAB's Other financing activities over 3 years: stood at $83000.0 in 2018, then surged by 36.14% to $113000.0 in 2019, then plunged by 84.07% to $18000.0 in 2020.
  • Per Business Quant, the three latest LAB Other financing activities figures stand at $18000.0 (Q2 2020), $357000.0 (Q1 2020), and $113000.0 (Q3 2019).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Standard Biotools 448.37 Mn -6.80 Mn 11.31 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2020 18,000.00
Jun 30, 2020 18,000.00
Mar 31, 2020 357,000.00
Mar 31, 2020 357,000.00
Sep 30, 2019 113,000.00
Sep 30, 2019 113,000.00
Jun 30, 2019 15,000.00
Jun 30, 2019 15,000.00
Dec 31, 2018 83,000.00
Dec 31, 2018 83,000.00
Sep 30, 2018 141,000.00
Sep 30, 2018 141,000.00
Jun 30, 2018 2.56 Mn
Jun 30, 2018 2.56 Mn
Mar 31, 2018 82,000.00
Mar 31, 2018 82,000.00